News headlines about Akebia Therapeutics (NASDAQ:AKBA) have been trending somewhat positive this week, Accern reports. The research group identifies positive and negative media coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Akebia Therapeutics earned a news sentiment score of 0.03 on Accern’s scale. Accern also gave media stories about the biopharmaceutical company an impact score of 46.6039178365883 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

Here are some of the news articles that may have effected Accern’s analysis:

How to Become a New Pot Stock Millionaire

Shares of AKBA traded down $0.05 during mid-day trading on Tuesday, hitting $9.90. 99,869 shares of the company’s stock traded hands, compared to its average volume of 439,763. Akebia Therapeutics has a 1 year low of $9.00 and a 1 year high of $20.25. The stock has a market capitalization of $548.22, a PE ratio of -5.59 and a beta of 1.10.

Akebia Therapeutics (NASDAQ:AKBA) last issued its quarterly earnings results on Monday, March 12th. The biopharmaceutical company reported $0.25 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.36) by $0.61. The company had revenue of $87.32 million for the quarter, compared to analysts’ expectations of $66.00 million. Akebia Therapeutics had a negative return on equity of 100.28% and a negative net margin of 43.21%. analysts forecast that Akebia Therapeutics will post -2.63 earnings per share for the current fiscal year.

A number of research firms recently weighed in on AKBA. BidaskClub downgraded Akebia Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Thursday, March 15th. Mizuho set a $24.00 target price on Akebia Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, March 7th. ValuEngine downgraded Akebia Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, March 13th. Zacks Investment Research downgraded Akebia Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, January 2nd. Finally, Piper Jaffray started coverage on Akebia Therapeutics in a research report on Monday, December 18th. They issued an “overweight” rating and a $26.00 price objective for the company. Two research analysts have rated the stock with a sell rating, two have given a hold rating and eight have issued a buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $22.20.

TRADEMARK VIOLATION NOTICE: “Somewhat Positive Media Coverage Somewhat Unlikely to Affect Akebia Therapeutics (AKBA) Share Price” was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this story on another site, it was copied illegally and reposted in violation of international copyright and trademark laws. The correct version of this story can be viewed at https://www.thecerbatgem.com/2018/04/17/somewhat-positive-media-coverage-somewhat-unlikely-to-affect-akebia-therapeutics-akba-share-price.html.

About Akebia Therapeutics

Akebia Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for patients with renal disease through hypoxia-inducible factor (HIF) biology. Its lead product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease in dialysis and non-dialysis patients.

Insider Buying and Selling by Quarter for Akebia Therapeutics (NASDAQ:AKBA)

Receive News & Ratings for Akebia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akebia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.